Dipeptidyl peptidase-4 inhibitors and angioedema: a class effect?
Dipeptidyl peptidase-4 (DPP-4) inhibitors have been reported to be generally well tolerated. However, angioedema has been reported as one of the rare adverse events of these drugs. We report a case in which angioedema induced by vildagliptin disappeared after changing to another DPP-4 inhibitor, alogliptin. Our case suggests that there is a difference in the risk of angioedema among DPP-4 inhibitors. To clarify this possibility, further investigation on the risk of angioedema among DPP-4 inhibitors is warranted.